Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 03 August 2015 | By Alan G. Minsk, JD
“Compliance” might be one of the most frequently-used terms in the healthcare industry. Compliance covers so many things and, in fact, is not merely a US issue. Life science companies must ensure global compliance, and this collection of feature articles in Regulatory Focus exclusively for RAPS members only scratches the surface.
In “Regulatory Quality Compliance Programs for Drugs and Biologics in the US and Canada,” Ryan Thompson, Vadim Lysenko, Mukesh Kumar, Giri Venkiteela and Lewis Lau provide an overview of compliance activities here and in the Great White North, as well as useful tools to strengthen quality compliance programs. Judy Fox piques our interest by revealing the “Untold Compliance Story Behind Sunshine Data.” You’ll have to read Judy’s article to learn about some challenges in presenting accurate and complete data to comply with the Sunshine Act, while finding a balance to preserve the integrity of physician interactions.
Mike Burke discusses what life science companies need to know about the Foreign Corrupt Practices Act. He offers practical and effective compliance strategies to consider.
Kathryn Ronalds and Nancy Ruth help us understand Health Canada’s requirements that apply to reprocessors of single use medical devices to be regulated as manufacturers. They identify potential effects of this new initiative.
Finally, Brian Dahl focusses us on the “Evolution of Board Responsibility for Compliance Program Oversight.” He examines the Office of the Inspector General’s expectations and how these have changed over time, in a manner corresponding to Audit Committee requirements of Sarbanes-Oxley.
On behalf of the Board of Editors, we hope you find value in this collection of articles and you learn something. Enjoy!
Tags: compliance